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Abstract
Introduction: Alport syndrome (AS) is a familial hematuria caused by mutations in COL4A3, COL4A4 and/or COL4A5
genes which lead to defects in glomerular ﬁltration barrier. So far, some founder mutations have been identiﬁed
with many of them being region- or ethnicity-speciﬁc. COL4A5 c.1871G>A, p.(Gly624Asp) pathogenic variant is
known to be prevalent in AS patients from Slovenia (6 out of 17), Hungary (3 out of 10) and Greece and lead to late
age at onset of end stage renal disease. In contrast to these populations, the mutation is considered to be rare in
the US, Northern and Western Europe or Japan. Here we show that the mutation was detected in 7 AS patients out
of 49 with genetically conﬁrmed diagnosis from Russia. Materials and methods: The population sample contained
76 apparently unrelated pediatric patients (1 to 17 years old) from diverse range of regions in the European part of
Russian Federation with conﬁrmed or suspected diagnosis of AS according to current guidelines. NGS sequencing
was performed using Ion PGM (AmpliSeq panel). Results: We conﬁrmed the diagnosis in 49 patients including 43
with X-linked AS (harboring COL4A5 gene mutations) and 1 with digenic COL4A5 and COL4A3 inheritance. Seven of
them were bearing the COL4A5 c.1871G>A, p.(Gly624Asp) mutation which corresponds to 14% frequency in the
sample. We demonstrate that the mutation is characterized by late age at onset of hematuria (>48 months) and
absence of proteinuria in childhood. The research was supported by RFBR grant 18-34-00708 to L.I.S. and
Minzdrav government grant №115022070016.
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